Intensified, sort duration chemotherapy of pediatric non-Hodgkin’s lymphoma

Clinical characteristics and outcome analysis of pediatric B‐cell non‐Hodgkin's lymphoma. Experience with FAB‐LMB 96 and UKCCSG B‐cell NHL guidelines in a developing country

“…This tumor is rare in very young children, and our observation of the highest number of patients within the 4–8‐year old age group is comparable to international experience, but certain authors have documented an average age of more than 10 years in B‐cell NHL 9,10 …”

Clinicopathologic Profile and Treatment Outcomes of Children With Diffuse Large B-cell Lymphomas: Experience From a Tertiary Cancer Center in India

“…In addition to our study there have been other studies from India in which MCP-842 was used. Two previous studies treating children with mature B-NHLs with MCP-842 protocol have reported outcomes similar to ours 7,13. In contrast, in another study from India, the 2-year EFS for patients with DLBCL treated with CHOP/BFM-89 was just 27.5% 9…”

“…Two previous studies treating children with mature B-NHLs with MCP-842 protocol have reported outcomes similar to ours. 7,13 In contrast, in another study from India, the 2-year EFS for patients with DLBCL treated with CHOP/BFM-89 was just 27.5%. 9 Pediatric DLBCL differs from adult onset disease in many ways including the way they behave to similar treatment, whilst R-CHOP-based protocols are generally the standard treatment in adult DLBCL 14 remission produced by them in children are quite short lasting.…”